

5 Reference List (PubMed)

1. GLOBOCAN. Cancer today: data visualization tools for exploring the global cancer burden in 2020. 2020. (Accessed 4/12/22, at <https://gco.iarc.fr/today/explore/>.)
2. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. *Nature* 2018;553:446-54. <https://pubmed.ncbi.nlm.nih.gov/29364287/>.
3. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. *Lancet Oncol* 2011;12:175-80. <https://pubmed.ncbi.nlm.nih.gov/21277552/>.
4. Jänne PA, Johnson BE. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. *Clin Cancer Res* 2006;12:4416s-20s. <https://pubmed.ncbi.nlm.nih.gov/16857820/>.
5. Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. *Signal Transduct Target Ther* 2019;4:5. <https://pubmed.ncbi.nlm.nih.gov/30854234/>.
6. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet* 2016;387:1540-50. <https://pubmed.ncbi.nlm.nih.gov/26712084/>.
7. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. *N Engl J Med* 2015;373:1627-39. <https://pubmed.ncbi.nlm.nih.gov/26412456/>.
8. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet* 2017;389:255-65. <https://pubmed.ncbi.nlm.nih.gov/27979383/>.
9. OPDIVO® (nivolumab) injection, for intravenous use [package insert]. Bristol-Myers Squibb Co.: Princeton, NJ; 2020.
10. TECENTRIQ® (atezolizumab) injection, for intravenous use [package insert]. Genentech, Inc.: South San Francisco, CA; 2020.
11. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. *N Engl J Med* 2020;382:41-50. <https://pubmed.ncbi.nlm.nih.gov/31751012/>.
12. Wu JY, Yu CJ, Shih JY. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations. *Clin Lung Cancer* 2019;20:e620-e30. <https://pubmed.ncbi.nlm.nih.gov/31327643/>.
13. Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. *N Engl J Med* 2017;376:629-40. <https://pubmed.ncbi.nlm.nih.gov/27959700/>.
14. Vyse S, Huang PH. Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer. *Expert Rev Anticancer Ther* 2022;22:3-16. <https://pubmed.ncbi.nlm.nih.gov/34913823/>.
15. Moores SL, Chiu ML, Bushey BS, et al. A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. *Cancer Res* 2016;76:3942-53. <https://pubmed.ncbi.nlm.nih.gov/27216193/>.

16. Jarantow SW, Bushey BS, Pardinas JR, et al. Impact of cell-surface antigen expression on target engagement and function of an epidermal growth factor receptor x c-MET bispecific antibody. *J Biol Chem* 2015;290:24689-704. <https://pubmed.ncbi.nlm.nih.gov/26260789/>.
17. Puri N, Salgia R. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. *J Carcinog* 2008;7:9. <https://pubmed.ncbi.nlm.nih.gov/19240370/>.
18. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. *EMBO J* 2000;19:3159-67. <https://pubmed.ncbi.nlm.nih.gov/10880430/>.
19. Sattler M, Reddy MM, Hasina R, Gangadhar T, Salgia R. The role of the c-Met pathway in lung cancer and the potential for targeted therapy. *Ther Adv Med Oncol* 2011;3:171-84. <https://pubmed.ncbi.nlm.nih.gov/21904579/>.
20. Organ SL, Tsao MS. An overview of the c-MET signaling pathway. *Ther Adv Med Oncol* 2011;3:S7-S19. <https://pubmed.ncbi.nlm.nih.gov/22128289/>.
21. Riess JW, Gandara DR, Frampton GM, et al. Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. *J Thorac Oncol* 2018;13:1560-8. <https://pubmed.ncbi.nlm.nih.gov/29981927/>.
22. Yoneda K, Imanishi N, Ichiki Y, Tanaka F. Treatment of Non-small Cell Lung Cancer with EGFR-mutations. *J UOEH* 2019;41:153-63. <https://pubmed.ncbi.nlm.nih.gov/31292359/>.
23. Robichaux JP, Elamin YY, Tan Z, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. *Nat Med* 2018;24:638-46. <https://pubmed.ncbi.nlm.nih.gov/29686424/>.
24. Yasuda H, Park E, Yun CH, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. *Sci Transl Med* 2013;5:216ra177. <https://pubmed.ncbi.nlm.nih.gov/24353160/>.
25. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Non-Small Cell Lung Cancer Version 3.2022. 2022. (Accessed June 24, 2022, at https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.)
26. Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. *J Clin Oncol* 2021;39:3391-402. <https://pubmed.ncbi.nlm.nih.gov/34339292/>.
27. Byeon S, Kim Y, Lim SW, et al. Clinical outcomes of EGFR exon 20 insertion mutations in advanced non-small cell lung cancer in Korea. *Cancer Res Treat* 2019;51:623-31. <https://pubmed.ncbi.nlm.nih.gov/30049203/>.
28. TAGRISSO® (osimertinib) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; January 2022.
29. Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. *J Thorac Oncol* 2013;8:179-84. <https://pubmed.ncbi.nlm.nih.gov/23328547/>.
30. GILOTRIF® (afatinib) tablets, for oral use. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; January 2018.
31. Genmab. Antibody technology platforms. (Accessed 3/4/21, at <https://www.genmab.com/research-innovation/antibody-technology-platforms/>.)

32. Labrijn AF, Meesters JI, de Goeij BE, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. *Proc Natl Acad Sci U S A* 2013;110:5145-50. <https://pubmed.ncbi.nlm.nih.gov/23479652/>.
33. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* 2012;12:252-64. <https://pubmed.ncbi.nlm.nih.gov/22437870/>.
34. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med* 2015;372:2018-28. <https://pubmed.ncbi.nlm.nih.gov/25891174/>.
35. Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced NonSmall-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. *J Clin Oncol* 2019;37:2518-27. <https://pubmed.ncbi.nlm.nih.gov/31154919/>.
36. Remon J, Hendriks LEL. Incorporating Immune Checkpoint Inhibitors into the Treatment of EGFR exon20ins NSCLC Tumors. *ASCO Daily News* 2021. <https://dailynews.ascopubs.org/doi/10.1200/ADN.21.200468/full/>.
37. Satoh M, Iida S, Shitara K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. *Expert Opin Biol Ther* 2006;6:1161-73. <https://pubmed.ncbi.nlm.nih.gov/17049014/>.
38. Castoldi R, Ecker V, Wiehle L, et al. A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity. *Oncogene* 2013;32:5593-601. <https://pubmed.ncbi.nlm.nih.gov/23812422/>.
39. Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trophocytosis. *Mol Cancer Ther* 2020;19:2044-56. <https://pubmed.ncbi.nlm.nih.gov/32747419/>.
40. Stewart R, Hammond SA, Oberst M, Wilkinson RW. The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer. *Journal for Immunotherapy of Cancer* 2014;2:29.
41. Grugan KD, Dorn K, Jarantow SW, et al. Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells. *mAbs* 2017;9:114-26. <https://pubmed.ncbi.nlm.nih.gov/27786612/>.
42. RYBREVANT® (amivantamab-vmjw) injection, for intravenous use [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; 2021.
43. FDA approves first targeted therapy for subset of non-small cell lung cancer. 2022. at <https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-subset-non-small-cell-lung-cancer>.
44. Dougherty L, Bhaumik A, D'Andrea D, Johnson A. Practical guide for infusion-related reaction (IRR) management with amivantamab for EGFR exon 20 insertion mutation non-small cell lung cancer (NSCLC): a nurse's view. Presented at: Oncology Nursing Society (ONS) Congress; April 27-May1, 2022; Anaheim, CA.
45. Minchom A, Viteri S, Bazhenova L, et al. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy. *Lung Cancer* 2022;168:74-82. <https://pubmed.ncbi.nlm.nih.gov/35597172/>.

46. ClinicalTrials.gov. A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer. 2019. <https://clinicaltrials.gov/ct2/show/NCT04077463>.
47. Shu CA, Goto K, Cho BC, et al. CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR mutant NSCLC. Poster presented at: the American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2021.
48. ClinicalTrials.gov. A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON). 2020. <https://clinicaltrials.gov/ct2/show/NCT04538664>.
49. Agrawal T, Artis E, Xie J, et al. PAPILLON: Randomized phase 3 study of amivantamab plus chemotherapy vs chemotherapy alone in EGFR exon20ins NSCLC. Abstract P76.74. J Thorac Oncol 2021;16:S621.
50. ClinicalTrials.gov. A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA). 2020. <https://clinicaltrials.gov/ct2/show/NCT04487080>.
51. Shreeve SM, Martinez M, Verheijen RB, et al. MARIPOSA: Randomized phase 3 study of first-line amivantamab + lazertinib vs osimertinib vs lazertinib in EGFR-mutant NSCLC. Abstract P76.73. J Thorac Oncol 2021;16:S620-S1.
52. Cho BC, et al. Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with Lazertinib, a 3rd-generation EGFR tyrosine kinase inhibitor, in advanced EGFR-mutant NSCLC. Presented at ESMO 2020.
53. Bauml J, Cho BC, Park K, et al. Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. Journal of Clinical Oncology 2021;39:9006-.
54. Shu CA, Goto K, Ohe Y, et al. CHRYSALIS-2 Cohort A mini-oral. Presented by Dr Catherine Shu at ASCO; June 3, 2022; Chicago, IL, USA.
55. Krebs MG, Johnson ML, Cho BC, et al. Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: Initial safety and pharmacokinetic results from the PALOMA study. Presented at AACR Annual Meeting; April 8-13, 2022.
56. U.S. Food and Drug Administration. Expedited Programs for Serious Conditions. 2022. (Accessed 6/16/2022, at <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf>.)
57. Guo MZ, Marrone KA, Spira A, Freeman K, Scott SC. Amivantamab: a potent novel EGFR/c-MET bispecific antibody therapy for EGFR-mutated non-small cell lung cancer. Oncology & Haematology 2017;17:42-7.
58. Tamirat MZ, Kurppa KJ, Elenius K, Johnson MS. Structural basis for the functional changes by EGFR exon 20 insertion mutations. Cancers (Basel) 2021;13:1120. <https://pubmed.ncbi.nlm.nih.gov/33807850/>.
59. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009;28 S24-31. <https://pubmed.ncbi.nlm.nih.gov/19680293/>.

60. Cho BC, Han JY, Kim SW, et al. A phase 1/2 study of lazertinib 240 mg in patients with advanced EGFR T790M-positive NSCLC after previous EGFR tyrosine kinase inhibitors. *J Thorac Oncol* 2022;17:558-67.
<https://pubmed.ncbi.nlm.nih.gov/34958928/>.
61. Krebs MG, Spira AI, Cho BC, et al. CHYRSALIS Metex14 mini-oral. Presented by Dr Matthew Krebs at ASCP; June 3, 2022; Chicago, IL, USA.
62. A study of amivantamab subcutaneous (SC) administration for the treatment of advanced solid malignancies. 2020. (Accessed 6/29/22, at <https://clinicaltrials.gov/ct2/show/NCT04606381>.)
63. ClinicalTrials.gov. A Study of Lazertinib and Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer. Janssen Research & Development, LLC. 2022.
<https://clinicaltrials.gov/ct2/show/NCT05388669>
64. ClinicalTrials.gov. A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer. 2021.
<https://clinicaltrials.gov/ct2/show/NCT04945733>.
65. ClinicalTrials.gov. A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer. 2022. <https://clinicaltrials.gov/ct2/show/NCT05379595>.